PPD Development, LP

Quick facts

Phase 2 pipeline

• Cohort A: vilobelimab
• Cohort B: paridiprubart
• Cohort C: bevacizumab · Oncology
  Bevacizumab is a monoclonal antibody that inhibits angiogenesis by binding to vascular endothelial growth factor A (VEGF-A).

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• PPD Development, LP portfolio CI brief
• PPD Development, LP pipeline updates RSS